Abstract: Objective To investigate the correlation between serum levels of DKK1 and β2-microglobulin and the multiple myeloma disease progress. Methods Sixty-six patients with multiple myeloma were selected as study group,and sixty-six healthy subjects were selected as control group. The serum levels of Wnt pathway inhibitor Dickkopf-1 （DKK1） and beta2-microglobulin were measured,and their associations with the incidence of multiple myeloma were analyzed. Results ① The serum levels of DKK1 and β2-microglobulin in the study group were significantly higher than those in the control group （P<0.05）. ② The differences of serum DKK1 and β2-microglobulin in different myeloma patients were statistically significant （P<0.05）; After multiple comparison,the serum levels of DKK1 and β2-microglobulin in stage II and III were all higher than those in stage I （P<0.05）,and the levels of DKK1 and β2-microglobulin in stage III were all higher than those in stage II （P<0.05）. ③The difference of serum DKK1 and β2-microglobulin in different stages was statistically significant （P <0.05）; After multiple comparison,the serum levels of DKK1 and β2-microglobulin in patients in renal insufficiency stage were higher than those in other periods （P<0.05）. Serum DKK1 and β2-microglobulin levels in patients in early stage and recurrence stage were higher than those in clinical remission stage （P<0.05）. Conclusion Serum DKK1 and β2-microglobulin levels are positively correlated to the severity of multiple myeloma. The detection of the two markscan effectively evaluate the patient's condition

Key words: Multiple myeloma, Serum DKK1, β2-microglobulin, Correlation